ATS
REGN icon

Ashton Thomas Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Ashton Thomas Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$850K Buy
1,369
+110
+9% +$74.9K 0.13% 156
2026
Q1 		$973K Buy
1,259
+45
+4% +$34.5K 0.12% 168
2025
Q4 		$938K Buy
1,214
+29
+2% +$19.7K 0.18% 112
2025
Q3 		$666K Sell
1,185
-7
-0.6% -$3.96K 0.09% 197
2025
Q2 		$626K Buy
1,192
+69
+6% +$38.5K 0.15% 149
2025
Q1 		$714K Buy
1,123
+313
+39% +$215K 0.2% 132
2024
Q4 		$577K Buy
810
+20
+3% +$16.8K 0.16% 135
2024
Q3 		$830K Buy
790
+75
+10% +$83.5K 0.16% 132
2024
Q2 		$755K Buy
+715
New +$693K 0.18% 128

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Ashton Thomas Securities's REGN Position: Q2 2026 in Review

Ashton Thomas Securities increased its Regeneron Pharmaceuticals (REGN) stake by 8.7% in Q2 2026, buying an estimated $74.9K and bringing the position to 1,369 shares worth $850K. The position accounts for 0.13% of the portfolio, ranked #156.

Ashton Thomas Securities first reported a position in REGN in Q2 2024 and has held it in 9 quarters since. The position peaked at $973K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ashton Thomas Securities held 1,369 shares of Regeneron Pharmaceuticals worth $850K as of Q2 2026.
  • Ashton Thomas Securities bought 110 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $74.9K.
  • Regeneron Pharmaceuticals made up 0.13% of Ashton Thomas Securities's portfolio in Q2 2026, its #156 holding.
  • Ashton Thomas Securities first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Ashton Thomas Securities's Regeneron Pharmaceuticals position peaked at $973K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ashton Thomas Securities's 13F filing for Q2 2026, filed 27 Jul 2026.